Inovio Pharmaceuticals Inc (INO) USD0.001

Sell:$1.92Buy:$1.98No change

Prices delayed by at least 15 minutes
Sell:$1.92
Buy:$1.98
Change:No change
Prices delayed by at least 15 minutes
Sell:$1.92
Buy:$1.98
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.

Key people

Jacqueline Elizabeth Shea
President, Chief Executive Officer, Director
Peter D. Kies
Chief Financial Officer
Laurent M. Humeau
Chief Scientific Officer
Steven Egge
Chief Commercial Officer
Michael Sumner
Chief Medical Officer
Simon X. Benito
Independent Chairman of the Board
Jay P. Shepard
Non-Executive Independent Vice Chairman of the Board
David B. Weiner
Director
Roger D. Dansey
Independent Director
Ann Calby Miller
Independent Director
Click to see more

Key facts

  • EPIC
    INO
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US45773H4092
  • Market cap
    $70.30m
  • Employees
    122
  • Shares in issue
    36.05m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.